Specific downregulation of death-associated protein kinase enhances Fas-mediated apoptosis in the human differentiated endometrial adenocarcinoma cell line, HHUA

Purpose of investigation: Death-associated protein kinase (DAPK) is a serine/threonine kinase that is well-known as a positive mediator of Fas-mediated apoptosis. Previous reports have shown that DAPK and Fas are expressed in human endometrial adenocarcinoma cells. In this study, we examined the effects of specific downregulation of DAPK expression on Fas-mediated apoptosis in the human endometrial adenocarcinoma cell line, HHUA. Methods and results: Transfection of DAPK small-interfering RNAs (siRNAs) into the HHUA cells reduced DAPK protein expression, and enhanced Fas-mediated apoptosis, in a dose-dependent manner. Conclusions: These results indicate that, in contrast to cases with other malignant tumor cells, DAPK negatively regulates Fas-mediated apoptosis in these human differentiated endometrial adenocarcinoma cells.

Death-associated protein kinase; Fas; Endometrial adenocarcinoma; siRNA

[1] Deiss L.P., Feinstein E., Berissi H., Cohen O., Kimchi A.: “Identification of a novel serine/threonine kinase and a novel 15kD protein as potential mediators of the gamma interferon-induced cell death”. Genes. Dev., 1995, 9, 15.

[2] Cohen O., Feinstein E., Kimchi A.: “DAP kinase is a Ca2+/calmodulin-dependent, cytoskeleton-associated protein kinase, with cell death-inducing functions that depend on its catalytic activity”. EMBO J., 1997, 16, 998.

[3] Cohen O., Inbal B., Kissil J.L., Raveh T., Berissi H., Spivak-Kroizaman T. et al.: “DAP kinase participates in TNF-alpha- and Fas-induced apoptosis and its function requires the death domain”. J. Cell Biol., 1999, 146, 141.

[4] Jang C.W., Chen C.H., Chen C.C., Chen J.Y., Su Y.H. et al.: “TGFβ induces apoptosis through Smad-mediated expression of DAP kinase”. Nat. Cell Biol., 2002, 4, 51.

[5] Raveh T., Droguett G., Horwitz M.S., De Pinho R.A., Kimchi A.: “DAP kinase activates a p19ARF/p53-mediated apoptotic checkpoint to suppress oncogenic transformation”. Nat. Cell Biol., 2001, 3, 1.

[6] Pelled D., Raveh T., Riebeling C., Fridkin M., Berissi H., Futerman A.H. et al.: “Death-associated protein (DAP) kinase plays a central role in ceramide induced apoptosis in cultured hippocampal neurons”. J. Biol. Chem., 2002, 277, 1957.

[7] Yamamoto M., Hioki T., Nakajima-Iijima S., Uchino S.: “DAP kinase activity is critical for C (2)-ceramide-induced apoptosis in PC12 cells”. Eur. J. Biochem., 2002, 269, 139.

[8] Wang W.J., Kuo J.C., Yao C.C., Chen R.H.: “DAP kinase induces apoptosis by suppressing integrin activity and disrupting matrix survival signals”. J. Cell Biol., 2002, 159, 169.

[9] Kissil J.L., Feinstein E., Cohen O., Jones P.A., Tsai Y.C., Knowles M.A. et al.: “DAP kinase loss of expression in various carcinoma and B-cell lymphoma cell lines: possible implications for role as tumor suppressor gene”. Oncogene, 1997, 15, 403.

[10] Inbal B., Cohen O., Polak-Charcon S., Kopolovic J., Vadai E., Eisenbach L. et al.: “DAP kinase links the control of apoptosis to metastasis”. Nature, 1997, 390, 180.

[11] Jin Y., Blue E.K., Dixon S., Hou L., Wysolmerski R.B., Gallagher P. J.: “Identification of a new form of death-associated protein kinase that promotes cell survival”. J. Biol. Chem., 2001, 276, 39667.

[12] Jin Y., Gallagher P.J.: “Antisense depletion of death-associated protein kinase promotes apoptosis”. J. Biol. Chem., 2003, 278, 51587.

[13] Bai T., Tanaka T., Yukawa K., Maeda M., Umesaki N.: “Reduced expression of death-associated protein kinase in human uterine and ovarian carcinoma cells”. Oncol. Rep., 2004, 11, 661.

[14] Tabibzadeh S., Babaknia A., Liu R., Zupi E., Marconi D., Romanini C.: “Site and menstrual cycle-dependent expression of proteins of the TNF receptor family, and BCL-2 oncoprotein and phase specific production of TNF-α in human endometrium”. Hum. Reprod., 1994, 10, 277.

[15] Yamashita H., Kumagai K., Inoki C., Ueki M., Sugimoto O., Otsuki Y.: “The expression of Fas antigen in human endometrium”. Acta. Obstet. Gynecol. Jpn., 1995, 47, 277.

[16] Watanabe H., Kanzaki H., Narukawa S., Inoue T., Katsuragawa H., Kaneko Y. et al.: “Bcl-2 and Fas expression in eutopic and ectopic human endometrium during the menstrual cycle in relation to endometrial cell apoptosis”. Am. J. Obstet. Gynecol., 1997, 176, 360.

[17] Tanaka T., Umesaki N.: “Cytokine regulation of apoptotic susceptibility in a human endometrial epithelial cell line”. J. Reprod. Immunol., 2000, 47, 105.

[18] Henshall D.C., Araki T., Schindler C.K., Shinoda S., Lan J.Q., Simon R.P.: “Expression of death-associated protein kinase and recruitment to the tumor necrosis factor signaling pathway following brief seizures”. J. Neurochem., 2003, 86, 1260.

[19] Li L., Tanaka T., Yukawa K., Akira S., Umesaki N.: “Irinotecan-induced ovarian follicular apoptosis is attenuated by deleting the kinase domain of death-associated protein kinase”. Int. J. Oncol., 2009, 34, 905.

[20] Nakatsuka S., Takakuwa T., Tomita Y., Hoshida Y., Nishii M., Yamaguchi M. et al.: “Hypermethylation of death-associated protein (DAP) kinase CpG island is frequent not only in B-cell but also in T- and natural killer (NK)/T-cell malignancies”. Cancer Sci., 2003, 94, 87.

[21] Esteller M., Sanchez-Cespedes M., Rosell R., Sidransky D., Baylin S.B., Herman J.G.: “Detection of aberrant promotor hypermethylation of tumor suppressor genes in serum DNA from non-small cell lung cancer patients”. Cancer Res., 1999, 59, 67.

[22] Sanchez-Cespedes M., Esteller M., Wu L., Nawroz-Danish H., Yoo G.H., Koch W.M. et al.: “Gene promotor hypermethylation in tumors and serum of head and neck cancer patients”. Cancer Res., 2000, 60, 892.

[23] Lee T.L., Leung W.K., Chan M.W.Y., Ng E.K.W., Tong J.H.M., Lo K.W. et al.: “Detection of gene promotor hypermethylation inthe tumor and serum of patients with gastric carcinoma”. Clin. Cancer Res., 2002, 8, 1761.

[24] Satoh A., Toyota M., Itoh F., Obata T., Sasaki Y., Suzuki H. et al.: “DNA methylation and histone deacetylation associated with silencing DAP kinase gene expression in colorectal and gastric cancers”. Br. J. Cancer, 2002, 86, 1817.

[25] Dong S.M., Kim H.S., Rha S.H., Sidransky D.: “Promotor hypermethylation of multiple genes in carcinoma of the uterine cervix”. Clin. Cancer Res., 2002, 7, 1982.

[26] Matsumoto H., Nagao M., Ogawa S., Kanehiro H., Hisanaga M., Ko S. et al.: “Prognostic significance of death-associated protein-kinase expression in hepatocellular carcinomas”. Anticancer Res., 2003, 23, 1333.

[27] Ishiwata I., Ishiwata C., Soma M., Arai J., Ishikawa H.: “Establishment of human endometrial adenocarcinoma cell line containing estradiol-17 beta and progesteron receptors”. Gynecol. Onc., 1984, 17, 281.

[28] Tang X., Wu W., Sun S.Y., Wistuba I.I., Hong W.K., Mao L.: “Hypermethylation of the death-associated protein kinase promotor attenuates the sensitivity to TRAIL-induced apoptosis in human non-small cell lung cancer cells”. Mol. Cancer Res., 2004, 2, 685.

[29] Jeon Y.K., Kim H., Park S.O., Choi H.Y., Kim Y.A., Park S.S. et al.: “Resistance to Fas-mediated apoptosis is restored by cycloheximide through the downregulation of cellular FLIPL in NK/T-cell lymphoma”. Lab. Invest., 2005, 85, 874.

[30] Schneider-Stock R., Kuester D., Ullrich O., Mittag H., Habold C., Boltze C. et al.: “Close localization of DAP-kinase positive tumour-associated macrophages and apoptotic colorectal cancer cells”. J. Pathol., 2006, 209, 95.

[31] Mikami M., Sakai K., Yoshiki J., Akiba Y., Kuboshiro K., Tsukazaki K. et al.: “Differentiation of endometrial carcinoma cell lines cultured in type I collagen gel and significance of sulfate lipid”. Acta. Obstet. Gynecol. Jpn., 1996, 48, S348.

[32] Tanaka T., Bai T., Toujima S.: “Establishment and characterization of monoclonal 5-fluorouracil-resistant cell lines derived from human endometrial adenocarcinoma”. Int. J. Oncol., 2010, 37, 731.